Home > Boards > US Listed > Biotechs > Motif Bio plc (MTFB) (MTFB)

24th Oct 2019 16:05 (Sharecast News) - Clinical-stage biopharmaceutical

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
MaximusProfiticus Member Profile
 
Followed By 146
Posts 7,305
Boards Moderated 1
Alias Born 03/13/14
160x600 placeholder
MaximusProfiticus   Friday, 11/15/19 07:58:31 AM
Re: None
Post # of 46 
24th Oct 2019 16:05
(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
The AIM-traded firm said the aerosol technology allowed the delivery of antibiotics "painlessly and rapidly" into skin and soft tissue, with low-pressure and focused delivery.

It said the research was being funded through a grant from the US Department of Defense - Congressionally Directed Military Infectious Diseases Research Program, to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield.

"When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible," said Motif Bio chief medical officer David Huang.

"The data generated from [research lead] Dr Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences